Adeno-associated virus (AAV) vectors achieve prolonged transgene expression in mouse myocardium and arteries in vivo: A comparative study with adenovirus vectors

International Journal of Cardiology

Volumn 90, Issue 2-3, 2003, Pages 229-238

  Vassalli, Giuseppe ^a,c   Büeler, Hansruedi ^b   Dudler, Jean ^a   Von Segesser, Ludwig K ^a   Kappenberger, Lukas ^a  

^a University of Lausanne Medical Center   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

AAV; Adeno associated virus; Gene transfer; Myocardium, Artery

Indexed keywords

GREEN FLUORESCENT PROTEIN; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; GENE EXPRESSION; GENE TARGETING; GENE TRANSFER; HEART MUSCLE; IN VIVO STUDY; MOUSE; MUSCLE CELL; NONHUMAN; PERICARDIUM; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSGENE;

EID: 0042885512     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(02)00554-5     Document Type: Article

References (51)

1. Ylä-Herttuala S., Martin J.F. Cardiovascular gene therapy. Lancet. 355:2000;213-222.
2. 165 as sole therapy for myocardial ischemia. Circulation. 98:1998;2800-2804.
3. Vale P.R., Losordo D.W., Milliken C.E., et al. Images in cardiovascular medicine: percutaneous myocardial gene transfer of phVEGF-2. Circulation. 100:1999;2462-2463.
4. Sylven C., Sarkar N., Ruck A., et al. Myocardial Doppler tissue velocity improves following myocardial gene therapy with VEGF-A165 plasmid in patients with inoperable angina pectoris. Coron Artery Dis. 12:2001;239-243.
5. Laitinen M., Hartikainen J., Hiltunen M.O., et al. Catheter-mediated VEGF gene transfer to human coronary arteries after angioplasty. Hum Gene Ther. 11:2000;263-270.
6. Kornovski R., Leon M.B., Fuchs S., et al. Electromagnetic guidance for catheter-based transendocardial injection: a platform for intramyocardial angiogenesis therapy. J Am Coll Cardiol. 35:2000;1031-1039.
7. Rosengart T.K., Lee L.Y., Patel S.R., et al. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg. 230:1999;466-470.
8. Mäkinen K., Laitinin M., Manninen H., Matsi P., Alhava E., Ylä-Herttuala S. Catheter-mediated VEGF gene transfer to human lower limb arteries after PTA. Circulation. 100:1999;I-770.
9. 165 in patient with ischemic limb. Lancet. 348:1996;370-374.
10. 165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 97:1998;1114-1123.
11. Lin H., Parmacek M.S., Morle G., Bolling S., Leiden J.M. Expression of recombinant genes in myocardium in vivo after direct injection of DNA. Circulation. 82:1990;2217-2221.
12. Wright M.J., Wightmann L.M.L., Lilley C., et al. In vivo myocardial gene transfer: optimization, evaluation and direct comparison of gene transfer vectors. Basic Res Cardiol. 96:2001;227-236.
13. Guzman R.J., Lemarchand P., Crystal R.G., Epstein S.E., Finkel T. Efficient gene transfer into myocardium by direct injection of adenovirus vectors. Circ Res. 73:1993;1202-1207.
14. Schulick A.H., Dong G., Newman K.D., Virmani R., Dichek D.A. Endothelium-specific in vivo gene transfer. Circ Res. 77:1995;475-485.
15. Vassalli G., Agah R., Qiao R., Aguilar C., Dichek D.A. A mouse model of arterial gene transfer: antigen-specific immunity is a minor determinant of the early loss of adenovirus-mediated transgene expression. Circ Res. 85:1999;e25-e32.
16. Jooss K., Ertl H.C., Wilson J.M. Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver. J Virol. 72:1998;2945-2954.
17. Tripathy S.K., Black H.B., Goldwasser E., Leiden J.M. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med. 2:1996;545-550.
18. Rolling F., Samuslki R.J. AAV as a viral vector for human gene therapy: generation of a recombinant virus. Mol Biotechnol. 3:1995;9-15.
19. Miao C.H., Snyder R.O., Schowalter D.B., et al. The kinetics of rAAV integration in the liver. Nat Genet. 19:1998;13-15.
20. Snyder R.O., Miao C.H., Patijn G.A., et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet. 16:1997;270-276.
21. Kessler P.D., Podsakoff G.M., Chen X., et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA. 93:1996;14082-14087.
22. Kaplitt M.G., Xiao X., Samulski R.J., et al. Long-term gene transfer in porcine myocardium after coronary infusion of an adeno-associate virus vector. Ann Thorac Surg. 62:1996;1669-1676.
23. Svensson E.C., Marshall D.J., Woodard K., et al. Efficient and stable transduction of cardiomyocytes after intramyocardial injection or intracoronary perfusion with recombinant adeno-associated virus vectors. Circulation. 99:1999;201-205.
24. Gnatenko D., Arnold T.E., Zolotukhin S., Nuovo G.J., Muzyczka N., Bahou W.F. Characterization of recombinant adeno-associated virus-2 as a vehicle for gene delivery and expression into vascular cells. J Invest Med. 45:1997;87-98.
25. Lynch C.M., Hara P.S., Leonard J.C., Williams J.K., Dean R.H., Geary R.L. Adeno-associated virus vectors for vascular gene delivery. Circ Res. 80:1997;497-505.
26. Rolling F., Nong Z., Pisvin S., Collen D. Adeno-associated virus-mediated gene transfer into rat carotid arteries. Gene Ther. 4:1997;757-761.
27. Samulski R.J., Chang L.S., Shenk T. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol. 63:1989;3822-3828.
28. Bett A.J., Haddara W., Prevec L., Graham F.L. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA. 91:1994;8802-8806.
29. Vincent-Lacaze N., Snyder R.O., Gluzman R., Bohl D., Lagarde C., Danos O. Structure of adeno-associated virus vector DNA following transduction of the skeletal muscle. J Virol. 73:1999;1949-1955.
30. Clesham G.J., Browne H., Efstathiou S., Weissberg P.L. Enhancer stimulation unmasks latent gene transfer after adenovirus-mediated gene delivery into human vascular smooth muscle cells. Circ Res. 79:1996;1188-1195.
31. Zhang Y., Chirmule N., Gao G.-P., Wilson J. CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: role of immature dendritic cells. J Virol. 74:2000;8003-8010.
32. Stripecke R., Carmen Villacres M., et al. Immune response to green fluorescent protein: implications for gene therapy. Gene Ther. 6:1999;1305-1312.
33. Jooss K., Yang Y., Fisher K.J., Wilson J.M. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol. 72:1998;4212-4223.
34. Ferrari F.K., Samulski T., Shenk T., Samulski R.J. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol. 70:1996;3227-3234.
35. Gerolami R., Uch R., Jordier F., et al. Gene transfer to hepatocellular carcinoma: transduction efficacy and transgene expression kinetics by using retroviral and lentiviral vectors. Cancer Gene Ther. 7:2000;1286-1292.
36. Gaetano C., Catalano A., Palumbo R., et al. Transcriptionally active drugs improve adenovirus vector performance in vitro and in vivo. Gene Ther. 7:2000;1624-1630.
37. Teramoto S., Ishii T., Matsuse T., Fukuchi Y. Recombinant adeno-associated virus vectors efficiently transduce foreign gene into bovine aortic endothelial cells: comparison with adenovirus vectors. Jpn J Pharmacol. 84:2000;206-212.
38. Xiao X., Li J., Samuslki R.J. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol. 72:1998;2224-2232.
39. Summerford C., Samulski R.J. Viral receptors and vector purification: new approaches for generating clinical-grade reagents. Nat Med. 5:1999;587-588.
40. Ritter T., Brandt C., Prösch S., et al. Stimulatory and inhibitory action of cytokines in the regulation of hCMV-IE promoter activity in human endothelial cells. Cytokine. 12:2000;1163-1170.
41. Von der Leyen H.E., Braun-Dullaeus R., Mann M.J., Zhang L., Niebauer J., Dzau V. A pressure-mediated non-viral method for efficient arterial gene and oligonucleotide transfer. Hum Gene Ther. 10:1999;2355-2364.
42. Su H., Lu R., Kan Y.W. Adeno-associated virus vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic hearts. Proc Natl Acad Sci USA. 97:2000;13801-13806.
43. Melo L.G., Agrawal R., Zhang L., et al. Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. Circulation. 105:2002;602-607.
44. Simons M., Bonow R.O., Chronos N.A., et al. Clinical trials in coronary angiogenesis: issues, problems, consensus. An expert panel summary. Circulation. 102:2000;e73-e86.
45. Elliger S.S., Elliger C.A., Lang C., Watson G.L. Enhanced secretion and uptake of beta-glucuronidase improves adeno-associated viral-mediated gene therapy of mucopolysaccharisosis type VII mice. Mol Ther. 5:2002;617-626.
46. Fraites T.J. Jr., Schleissing M.R., Shanely R.A., et al. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol Ther. 5:2002;571-578.
47. Grossman M., Rader D.J., Mulller D.W., et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med. 1:1995;1148-1154.
48. Fan L., Drew J., Dunckley M.G., Owen J.S. Efficient coexpression and secretion of anti-atherogenic human apolipoprotein AI and lecithin-cholesterol acyltransferase by cultured muscle cells using adeno-associated virus plasmid vectors. Gene Ther. 5:1998;1434-1440.
49. Guillot C., Mathieu P., Coathalem H., et al. Tolerance to cardiac allografts via local and systemic mechanisms after adenovirus-mediated CTLA4Ig expression. J Immunol. 164:2000;5258-5268.
50. Monahan P.E., Samulski R.J. AAV vectors. Is clinical success on the horizon? Gene Ther. 7:2000;24-30.
51. Bouchie A. Avigen AAV trial continues. Nat Biotechnol. 20:2002;119.